Connect Sign In
New guidance from the FDA and the National Comprehensive Cancer Network (NCCN) instructs clinicians to test for DPYD genetic variants before administering drugs commonly used to treat cancer to prevent potentially life-threatening reactions in patients whose genetics make them poor metabolizers for the drugs.
To help clinicians select the right DPYD genotyping test and interpret test results, ARUP Laboratories offers a new resource available here.
The resource, created by Ryan Nelson, PharmD, ARUP medical director of Precision Medicine, and Sherin Shaaban, MD, PhD, MSci, FACMG, ARUP medical director of Pharmacogenomics and Molecular Genetics, summarizes October updates from the FDA and NCCN. It then draws on information from the National Institutes of Health’s Genetic Testing Registry (GTR) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) to suggest what clinicians should prioritize in selecting testing. The resource also recommends a possible clinical workflow for DPYD genotyping.
ARUP also offers other educational resources related to DPYD genotyping, including:
- ARUP Consult Test Fact Sheet: Dihydropyrimidine Dehydrogenase (DPYD)
- ARUP Institute for Learning lecture: Pretreatment DPYD/DPD Testing: Clinical Updates and Considerations
- ARUP Article: Genetic Testing Gains Ground: DPYD Genotyping Can Be a Lifesaving Step Before Chemotherapy
- ARUP Consult topic: Germline Pharmacogenetics - PGx
- Featured testing at ARUP: Pharmacogenomic Testing
Lisa Carricaburu, lisa.carricaburu@aruplab.com
